{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T10:51:48Z","timestamp":1783075908964,"version":"3.54.6"},"reference-count":21,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2003,5,1]],"date-time":"2003-05-01T00:00:00Z","timestamp":1051747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2003,5]]},"DOI":"10.1016\/s0278-5846(02)00357-3","type":"journal-article","created":{"date-parts":[[2003,4,23]],"date-time":"2003-04-23T23:52:44Z","timestamp":1051141964000},"page":"535-538","source":"Crossref","is-referenced-by-count":10,"title":["Effects of the CYP2C19 genotype and cigarette smoking on the single oral dose pharmacokinetics and pharmacodynamics of estazolam"],"prefix":"10.1016","volume":"27","author":[{"given":"Toshiaki","family":"Aoshima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Fukasawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Otsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoyuki","family":"Okuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisa","family":"Gerstenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatomo","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Ohkubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunobu","family":"Sugawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Otani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/S0278-5846(02)00357-3_BIB1","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/clpt.1990.12","article-title":"Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole","volume":"47","author":"Andersson","year":"1990","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/S0278-5846(02)00357-3_BIB2","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/clpt.1989.40","article-title":"Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype","volume":"45","author":"Bertilsson","year":"1989","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/S0278-5846(02)00357-3_BIB3","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/0009-9236(95)90053-5","article-title":"Genetic analysis of the S-mephenytoin polymorphism in a Chinese population","volume":"58","author":"de Morais","year":"1995","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/S0278-5846(02)00357-3_BIB5","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0076-6879(96)72025-6","article-title":"Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism","volume":"272","author":"Goldstein","year":"1996","journal-title":"Methods Enzymol."},{"key":"10.1016\/S0278-5846(02)00357-3_BIB4","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/00008571-199412000-00001","article-title":"Biochemistry and molecular biology of the human CYP2C subfamily","volume":"4","author":"Goldstein","year":"1994","journal-title":"Pharmacogenetics"},{"key":"10.1016\/S0278-5846(02)00357-3_BIB6","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1176\/ajp.134.5.559","article-title":"Absorption rate, blood concentrations, and early response to oral chlordiazepoxide","volume":"134","author":"Greenblatt","year":"1977","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/S0278-5846(02)00357-3_BIB7","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1469-8986.1973.tb00801.x","article-title":"Quantification of sleepiness: a new approach","volume":"10","author":"Hoddes","year":"1973","journal-title":"Psychophysiology"},{"key":"10.1016\/S0278-5846(02)00357-3_BIB8","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/00004850-199510030-00002","article-title":"Effects of various factors on steady-state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine","volume":"10","author":"Ishida","year":"1995","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/S0278-5846(02)00357-3_BIB9","first-page":"460","article-title":"Flunitrazepan metabolism by cytochrome P450s 2C19 and 3A4","volume":"29","author":"Kilicarslan","year":"2001","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/S0278-5846(02)00357-3_BIB10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3109\/00498258609043501","article-title":"Metabolism of 14C-estazolam in dogs and humans","volume":"16","author":"Machinist","year":"1986","journal-title":"Xenobiotica"},{"key":"10.1016\/S0278-5846(02)00357-3_BIB11","first-page":"125","article-title":"Cigarettes and drug therapy: pharmacokinetic and pharmacodynamic considerations","volume":"9","author":"Miller","year":"1990","journal-title":"Clin. Pharm."},{"key":"10.1016\/S0278-5846(02)00357-3_BIB12","doi-asserted-by":"crossref","first-page":"525","DOI":"10.2116\/analsci.18.525","article-title":"Determination of estazolam in plasma by high-performance liquid chromatography with solid-phase extraction","volume":"18","author":"Miura","year":"2002","journal-title":"Anal. Sci."},{"key":"10.1016\/S0278-5846(02)00357-3_BIB13","first-page":"264","article-title":"Dissociative change in antiaggressive and muscle relaxant actions of S-triazolobenzodiazepine (D-40TA) by repeated administration and phenobarbital pretreatment, and its relation to metabolism","volume":"32","author":"Nakajima","year":"1973","journal-title":"J. Takeda Res. Lab."},{"key":"10.1016\/S0278-5846(02)00357-3_BIB14","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/hup.470070506","article-title":"Steady-state serum kinetics of zotepine","volume":"7","author":"Otani","year":"1992","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/S0278-5846(02)00357-3_BIB15","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0893-133X(96)00165-0","article-title":"Effects of genetically determined S-mephenytoin 4-hydroxylation status and cigarette smoking on the single-dose pharmacokinetics of oral alprazolam","volume":"16","author":"Otani","year":"1997","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/S0278-5846(02)00357-3_BIB16","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/00007691-200206000-00008","article-title":"No effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of estazolam","volume":"24","author":"Otsuji","year":"2002","journal-title":"Ther. Drug Monit."},{"issue":"Suppl. 3A","key":"10.1016\/S0278-5846(02)00357-3_BIB17","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/0002-9343(90)90279-M","article-title":"Efficacy of estazolam: the United States clinical experience","volume":"88","author":"Pierce","year":"1990","journal-title":"Am. J. Med."},{"issue":"Suppl. 3A","key":"10.1016\/S0278-5846(02)00357-3_BIB18","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/0002-9343(90)90280-Q","article-title":"Safety of estazolam: the United States clinical experience","volume":"88","author":"Pierce","year":"1990","journal-title":"Am. J. Med."},{"key":"10.1016\/S0278-5846(02)00357-3_BIB19","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1053\/cp.1999.v66.103379001","article-title":"Effect of the gene dosage of CYP2C19 on diazepam metabolism in Chinese subjects","volume":"66","author":"Qin","year":"1999","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/S0278-5846(02)00357-3_BIB20","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1177\/106002809502901113","article-title":"Cigarette smoking and clinically significant drug interactions","volume":"29","author":"Schein","year":"1995","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/S0278-5846(02)00357-3_BIB21","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/00007691-199708000-00001","article-title":"Single-dose pharmacokinetics and pharmacodynamics of oral triazolam in relation to cytochrome P450 2C19(CYP2C19) activity","volume":"19","author":"Yasui","year":"1997","journal-title":"Ther. Drug Monit."}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584602003573?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584602003573?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,3,6]],"date-time":"2019-03-06T22:32:31Z","timestamp":1551911551000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584602003573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,5]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2003,5]]}},"alternative-id":["S0278584602003573"],"URL":"https:\/\/doi.org\/10.1016\/s0278-5846(02)00357-3","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2003,5]]}}}